md-medicaldata


Go to content

VALIDACIJA I JEZIČKA ADAPTACIJA NA SRPSKI JEZIK: SKALA OCENE NEUROPATSKIH SIMPTOMA I ZNAKOVA IZ UNIVERZITETA U LIDSU

VALIDATION AND LINGUISTIC ADAPTATION TO SERBIAN LANGUAGE: LEEDS UNIVERSIYTY ASSESSMENT OF NEUROPATHIC SYMPTOMS AND SIGNS SCORE

Authors

 

Olivera Jovanikić1, Milić Veljović2, Gordana Anđelić3, Nebojša Damjanović2, Milan Knežević4
1 Klinika za neurohirurgiju Vojnomedicinska Akademija, Beograd, Srbija,
2 Klinika za anesteziologiju i intenzivnu terapiju, Vojnomedicinska Akademija, Beograd, Srbija,
3 Institut za medicinska Istraživanja, Vojnomedicinska Akademija, Beograd, Srbija,
4 Faculty of Medicine and Public Health Sciences ULPGC, Hospital Universitario Insular, Las Palmas, Spain

 

• The paper was received on 12.11.2015. / Accepted on 12.12.2015.

 

Abstract

 

Background: Diagnosis and treatment of neuropathic pain is important, but at the same time very difficult clinical problem.
Aim: Serbian adaptation of the version of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) score provides identification of neuropathic pain without the help and need for a clinician. We compare results of the pain DETECT and adaptation and  validation of the LANSS score in the Serbian population in this investigation.
Material and Methods: For the linguistic validation of LANSS, translation and back-translation method was used to adapt LANSS into Serbian language. A 78 patients were included in this study.  The Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), Visual Annalogue Score (VAS) and pain DETECT Scales were performed twice for every patient. The patients were examined and diagnosed as having nociceptive or neuropathic pain by nureses and neurosurgeon, who were blind for  LANSS, VAS and pain DETECT scores.
Results: The comparatiom of results the first and second scpres by the McNemar test indicated that LANSS scores were reliable. The sensitivity and specificity of the scale were found to be 93% and 95% respectively, positive predictive value 0,33 and negative predictive value 0,89.
Conclusion: The using of the LANSS scores for the diagnosis of neuropathic pain may help our colleagues as a good and trustworthy tool in daily clinical practice.

 

 

References

 

  1. Kopf A. and Patel NB. Ed. Management in neuropathic pain. In: Guide to Pain Management in Low-Resource Settings. IASP® • SEATTLE; 2010. Berlin.

  2. Cappelleri J, Bienen EJ, Koduru V, Sadosky A. Measurement properties of painDETECT by average pain severity. ClinicoEconomics and Outcomes Research 2014;6:497-504.
  3. Chan CW, Peng P. Failed back surgery syndrome. Pain Med. 2011; 12(4):577-606.
  4. Dobson JL, McMillan J, and Li L. Benefits of exercise intervention in reducing neuropathic pain. Frontiers in cellular neuroscience 2014; 8(102): 1-9.
  5. Deranovic Dobrota V, Hrabac P, Skegro D, Smiljanic R, Dobrota S, Prkacin I, et al. The impact of neuropathic oain and otehr comorbidities on qualitz of life in patients with diabetes. Health and Qualitz of Life Outcomes 2014; 12: 171-8.
  6. Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. A cross-sectional study examining the psychometric properties of the painDETECT measure in neuropathic pain. J Pain Res. 2015 Apr 15;8:159-67.
  7. Huffman C, Stacey BR, Tuchman M, Burbridge C, Li C, Parsons B, Pauer L. et al. Efficacy and Safety of Pregabalin in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy and Pain on Walking. Clin J Pain. 2015; 6: 125-129.
  8. Sakai Y, Ito K, Hida T, Ito S, Harada A. Neuropathic pain in elderly patients with chronic low back pain and effects of pregabalin: a preliminary study. Asian Spine J. 2015; 9(2): 254-62.
  9. Ferreira-Valente MA., Pais-Ribeiro JL, Jensen MP.Validity of four pain intensity rating scales.  Pain. 2011; 152(10): 2399-404.
  10. Moulin DE, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA. et al. Pharmacological management of chronic neuropathic pain: Revised consensus statemnet from the Canadian Pain Society. Pain Res Manag 2014; 19(6): 328-35.
  11. Caroll IR, Younger JW, Mackey SC. Pain quality predicts lidocaine analgesia amnog patients with suspected neuropathic pain. Pain Med 2010; 11(4): 617-21.
  12. Brod M, Blum SI, Bushnell DM, Ramasamy A. Development and validation of the Diabetic Peripheral Neuropathic Pain Impact (DPNPI) measure, a patient-reported outcome measure.Qual Life Res. 2015 Jun 12. [Epub ahead of print]
  13. Schreiber AK, Nones CF, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain: Physiopathology and treatment.World J Diabetes. 2015 Apr 15;6(3):432-44.
  14. Zheng C, Ou W, Shen H, Zhou Z, Wang J. Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies. Biomed Res Int. 2015;6:807-56.
  15. Lolignier S, Eijkelkamp N, Wood JN. Mechanical allodynia. Eur J Phzsiol 2015; 467: 133-9.
  16. National Institute of Neurological Disorders and Stroke. Peripheral neuropathy fact sheet. 2013; Available from:
    http:// www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm.
  17. Ellis JJ, Sadosky AB, Ten Eyck LL, Mudumby P, Cappelleri JC, Ndehi L, et al. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.BMC Health Serv Res. 2015; 15: 159.
  18. Zheng C , Ou W, Shen H, Zhou Z, Wang J. Combined therapy of diabetic peripheral neuropathy with breviscapine and mecobalamin: a systematic review and a meta-analysis of Chinese studies. Biomed Res Int. 2015; 6: 807-56.
  19. Pang B, Zhao LH, Zhou Q, Zhao TY, Wang H, Gu CJ, Tong XL. Application of berberine on treating type 2 diabetes mellitus. Int J Endocrinol 2015; 9: 057-094.
  20. Akamine T, Koyanagi S, Kusunose N, Hashimoto H, Taniguchi M, Matsunaga N, Ohdo S. Dosing time-dependent changes in the analgesic effect of pregabalin on diabetic neuropathy in mice. J Pharmacol Exp Ther 2015; 354(1): 65-72.
  21. Jack M, Wright D. Role of advanced  glycation endproduct and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res 2012; 159: 355-65.
  22. Ngyen DV, Shaw LC, Grant MB. Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol (Lausanne) 2012; 3:170-7.
  23. Talbot S, Couture R. Emerging role  of microglial kinin B1 receptor in diabetic pain neuropathy. Exp Neurol 2012; 234: 373-81.
  24. Park CH, Jung SH, Han CG. Effect of  intravenous lidocaine on the neuropathic pain of failed back surgery syndrome. Korean J Pain 2012; 25(2): 94-8.
  25. Thomson S. Failed back surgery syndrome – definition, epidemiology and demographics. British Journal of Pain 2013; 7 (1): 56-9.
  26. Milan Knezevic and Gordana Andjelic. Different aspects of orofacial pain (part IV) headache as a consequence of trigeminal nerve affectation. MD-Medical Data 2013; 5(4): 399-405.
  27. Trang T, Beggs S, Salter MW. Brain-derived neurotrophic factor  from microglia : a molecular substrate  for neuropatic pain. Neuron Glia Biol 2011; 7: 99-108.
  28. Fischer TZ,Waxman SG. Neuropathic pain in diabetes-evidence for a central mechanism. Nat Rev Neurol 2010; 6: 462-6.
  29. Zhuo M, Wu G, Wu LJ. Neuronal and microglial mechanisms of neuropathic pain. Mol Brain 2011; 4: 31-4.
  30. Leung L, Cahill CM. TNF-α and neuropathic pain-review. J Neuroinflammation 2010; 7: 27-34.
  31. Wen YR, Tan PH, Cheng JK, Liu YC, Ji RR.  Microglia: a promissing  target for treating  neuropathic and  postoperative pain, and morphine tolerance. J Formos Med Assoc. 2011; 110: 487-94.
  32. Nadeau  S, Filali M, Yhang J, Kerr BJ, Rivest S, Soulet D. Functionel recovery after periferal nerve injury is dependent  on the proinflammatory cytokines IL-1β and TNF: implications  for neuropathic pain. J Neurosci 2011; 31: 12533-42.
  33. Xu Q, JakshTL. A brief comparisson of the pazthophysiology of inflammatory versus neuropathic pain. Curr Opin Anesthesiol 2011; 24: 400-7.
  34. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010; 31: 24-31.
  35. Maixner DV, Weng HR. The role of glycogen syntase kinase 3 beta in neuroinflammation and pain J Pharma Pharmacol 2013; 1:1.
  36. Gosselin RD, Suter MR, Ji RR, Decostered I. Glial cells and chronic pain. Neuroscientist 2010; 16: 519-31.
  37. Olivera Jovanikic, Goran Pavlicevic, Gordana Andjelic, Milic Veljovic, Nebojsa Damjanovic, Ana Roganovic, Ivana Lecic. Treatment of severe acute pain during herpes zoster rash with ganglional and neural block and thus preventing postherpetic neuralgia.

    MD-Medical Data 2015; 7(3): 241-244.
  38. Јaved S, Petropoulos IN, Alam U, Malik RA. Treatmen of painful diabetic neuropathy. Ther Adv Cronic Dis 2015; 6(1): 15-28.
  39. Carrol IR, Younger JW, Mackey SC. Pain Quality predicts lidocain analgesia among patients with suspected neuropathic pain. Pain Med 2010; 11(4): 617-21.
  40. Tavakoli M, Asghar O, Alam U, Petropoulos IN, Fadavi H, Malik RA. Novel insights on diagnosis, cause and treatment of diabetic neuropaty: focus on painful diabetic neuropathy.Тhеr Adv Endocrinl Metab 2010; 1(2): 69-88.
  41. Schreiber AK, Nones CFM, Reis RC, Chichorro JG, Cunha JM. Diabetic neuropathic pain : physiopathology and treatment. Worl J Diabetes 2015; 6(3): 432-44.
  42. Benzon HT. The neuropathic pain scales. Reg Anesthesioa and Pain Med 2005; 30(5): 417-21.
  43. List T1, Mojir K, Svensson P, Pigg M. A new protocol to evaluate the effect of topical anesthesia. Anesth Prog. 2014; 61(4): 135-44.
  44. Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales.  Pain. 2011; 152(10): 2399-404.
  45. Hjermstad MJ1, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S. European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011; 41(6): 1073-93.
  46. Kaku M, Vinik A, Simpson DM. Pathways in the diagnosis and management of diabetic polyneuropathy. Curr Diab Rep 2015; 15(6): 609.
  47. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms of neuropathic pain.

    Pain 2003; 102: 1-8.
  48. Tesfaye S., Boulton AJ., Dickenson AH. Mechanisms and management of diabetic peinful distal symmetrical polyneuropathy. Diabetes Care 2013; 36: 2456-65.
  49. Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Arrea L, Haanpaa M, Jensen TS, Serra J, Treede RD. EFNS guidelines on neuropathica pain assessment : revised 2009. European J Neurol 2010; 17: 1010-8.
  50. Manasitirotis C, Papanas N, Veletza S, Maltezos E. APOE gene polymorphisms and diabetic peripheral neuropathy. Arch Med Sci 2012; 8(4): 583-8.
  51. Nouri MN, Ahmed A, Bril V, Orszag A, Ng E, Nwe P, Perkins BA. Diabetic neuropathy and axon reflex-mediated neurogenic vasodilatation in type 1 diabetes. PloS One 2012; 7(4): e34807
  52. BouhassiraD, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, Rostaing S, Lantieri-Minet M, Collin E, Grisart J, Boureau  F. Development and validation of the Neuropathic Pain Inventory Index. Pain 2004; 108: 248-57.
  53. De la Calle J-L, De Andres J, Peres M, Lopez V. Add-on teratment with pregabalin for patients with uncontrolled neuropathic pain who have been referred  to pain clinics. Clin Drug Investig 2014; 34: 833-44.
  54. Bennett M. The LANSS Pain Scale: The Leeds assessment of neuropathic symptoms and signs. Pain 2001; 92: 147-157.
  55. Robinson-Papp J, George MC, Dorfman D, Simpson DM. Barriers to Chronic Pain Measurement: A Qualitative Study of Patient Perspectives. Pain Med. 2015 Feb 17. doi: 10.1111/pme.12717. [Epub ]
  56. List T1, Mojir K, Svensson P, Pigg M. A new protocol to evaluate the effect of topical anesthesia. Anesth Prog. 2014;61(4):135-44.

    Ferreira-Valente MA., Pais-Ribeiro JL, Jensen MP.Validity of four pain intensity rating scales.  Pain. 2011; 152(10): 2399-404.
  57. Hjermstad MJ1, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S. European Palliative Care Research Collaborative (EPCRC). Studies comparing Numerical Rating Scales, Verbal Rating Scales, and Visual Analogue Scales for assessment of pain intensity in adults: a systematic literature review. J Pain Symptom Manage. 2011; 41(6): 1073-93.
  58. Yamamoto H, Sakura S, Wada M, Shido A. A prospective, randomized comparison between single- and multiple-injection techniques for ultrasound-guided subgluteal sciatic nerve block.Anesth Analg. 2014; 119(6): 1442-8.
  59. Likar R, Demschar S, Kager I, Neuwersch S, Pipam W, Sittl R. Тreatment of localized neuropathic pain of diffrent etiologies with the 5% lidocain medicated plaster – a case series. Int J Gen Med 2015; 8: 9-14.
  60. Eijkelkamp N, Linley JE, Baker MD, Minett MS, Cregg R, Werdehausen R, et al. Neurological perspectives on voltage-gated sodium channels. Brain 2012; 135: 2585-612.
  61. Krumova EK, Zeller M, Westermann A, Maier C. Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers.Pain. 2012;153(2):273-80.
  62. Harvey S, Corey J, Townley K. A modification of the single-penetration, dual-injection technique for combined sciatic and saphenous nerve blocks.Reg Anesth Pain Med. 2014; 39(6): 561.
  63. Liu SS, Ngeow J, John RS. Evidence basis for ultrasound-guided block characteristics: onset, quality, and duration.Reg Anesth Pain Med. 2010; 35(2 Suppl): S26-35.
  64. Barbosa FT, Barbosa TR, da Cunha RM, Rodrigues AK, da Silva Ramos FW, de Sousa-Rodrigues CF. Anatomical basis for sciatic nerve block at the knee level. Braz J Anesthesiol. 2015; 65(3): 177-9.
  65. Kroin JS, Buvanendran A, Williams DK, Wagenaar B, Moric M, Tuman KJ, Kerns JM. Local anesthetic sciatic nerve block and nerve fiber damage in diabetic rats.Reg Anesth Pain Med. 2010; 35(4): 343-50.
  66. Lee YF., Lin CC., Cheng JS., Chen GS. Nerve conduction block in diabetic rats using high-intensity focused ultrasound for analgesic applications.Br J Anaesth. 2015;114(5):840-6.
  67. Lee YF, Lin CC, Cheng JS, Chen GS. High-intensity focused ultrasound attenuates neural responses of sciatic nerves isolated from normal or neuropathic rats. Ultrasound Med Biol 2015; 41(1): 132-42.
  68. Narouze SN, Provenzano DA. Sonographically guided cervical facet nerve and joint injections: why sonography? J Ultrasound Med. 2013; 32(11): 1885-96.
  69. Karmakar MK., Li JW., Kwok WH., Hadzic A.Ultrasound-guided lumbar plexus block using a transverse scan through the lumbar intertransverse space: a prospective case series. Reg Anesth Pain Med 2015; 40(1): 75-81
  70. Salinas FV. Ultrasound and review of evidence for lower extremity peripheral nerve blocks.Reg Anesth Pain Med. 2010; 35 (2 Suppl): S16-25.
  71. Keplinger M, Marhofer P, Marhofer D, Schroegendorfer K, Haslik W, Zeitlinger M, Mayer CV, Kettner SC. Effective local anaesthetic volumes for sciatic nerve blockade: a clinical evaluation of the ED99. Anaesthesia 2015; 70(5): 585-90.
  72. Athanasakis K, Petrakis I, Karampli E, Vitsou E, Lyras L, Kyriopoulos J. Pregabalin versus gabapentin in the management of peripheral neuropathic pain associated with post-herpetic neuralgia and diabetic neuropathy: a cost effectiveness analysis for the Greek healthcare setting.
  73. BMC Neurol. 2013; 13: 56.
  74. Jeong JS, Shim JC, Jeong MA, Lee BC, Sung IH.Minimum effective anaesthetic volume of 0.5% ropivacaine for ultrasound-guided popliteal sciatic nerve block in patients undergoing foot and ankle surgery: determination of ED50 and ED95. Anaesth Intensive Care. 2015;43(1):92-7.

PDF Jovanikić O. et al. • MD-Medical Data 2015;7(4): 279-286

Naslovna | Revija | Galerija | Dešavanja | Instrukcije | Redakcija | Izdavač | Prijatelji sajta | Saradnja | Kontakt | Site Map


Back to content | Back to main menu